• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Perioperative Complications Associated With Limited Surgical Fasciectomy After Collagenase Clostridium Histolyticum for Dupuytren Contracture.胶原酶注射治疗掌腱膜挛缩症后行有限掌腱膜切除术的围手术期并发症
Hand (N Y). 2024 Sep;19(6):946-950. doi: 10.1177/15589447231160288. Epub 2023 Apr 4.
2
Collagenase clostridium histolyticum for the treatment of Dupuytren's contracture: systematic review and economic evaluation.溶组织梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症:系统评价与经济学评估
Health Technol Assess. 2015 Oct;19(90):1-202. doi: 10.3310/hta19900.
3
Surgery for Dupuytren's contracture of the fingers.手指掌腱膜挛缩症的手术治疗
Cochrane Database Syst Rev. 2015 Dec 9;2015(12):CD010143. doi: 10.1002/14651858.CD010143.pub2.
4
Surgical Management of Dupuytren Disease: A Systematic Review and Network Meta-analyses.《掌腱膜挛缩症的外科治疗:系统评价和网络荟萃分析》。
Hand (N Y). 2024 Nov;19(8):1283-1292. doi: 10.1177/15589447231174175. Epub 2023 May 28.
5
Collagenase clostridium histolyticum injection versus limited fasciectomy for the treatment of Dupuytren's disease: a systematic review and meta-analysis of comparative studies.胶原酶注射与有限筋膜切开术治疗杜普伊特伦挛缩症的比较:系统评价和荟萃分析。
Arch Orthop Trauma Surg. 2024 Jan;144(1):527-536. doi: 10.1007/s00402-023-05004-8. Epub 2023 Sep 4.
6
Outcomes of limited fasciectomy, needle fasciotomy and collagenase injection for Dupuytren's disease: a systematic review and meta-analysis of individual patient data.掌腱膜挛缩症的有限筋膜切除术、经皮筋膜切开术和胶原酶注射治疗结果:个体患者数据的系统评价和荟萃分析
J Hand Surg Eur Vol. 2025 Jul;50(7):878-890. doi: 10.1177/17531934251338349. Epub 2025 May 20.
7
Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.溶组织梭状芽孢杆菌胶原酶治疗掌腱膜挛缩症:一项系统评价
Br Med Bull. 2016 Jun;118(1):149-58. doi: 10.1093/bmb/ldw020. Epub 2016 May 5.
8
Effectiveness and Safety of Dupuytren Contracture Treatments: A Systematic Review and Meta-Analysis Using the GRADE Approach.掌腱膜挛缩症治疗的有效性和安全性:采用GRADE方法的系统评价和荟萃分析
Plast Reconstr Surg. 2025 Sep 1;156(3):375e-384e. doi: 10.1097/PRS.0000000000011816. Epub 2024 Oct 15.
9
Limited Fasciectomy Versus Collagenase Clostridium histolyticum for Dupuytren Contracture: A Propensity Score Matched Study of Single Digit Treatment With Minimum 5 Years of Telephone Follow-Up.局限性筋膜切除术与胶原酶注射治疗掌腱膜挛缩症的对比:一项采用倾向性评分匹配法的单指治疗病例研究,最少电话随访 5 年。
J Hand Surg Am. 2021 Oct;46(10):888-895. doi: 10.1016/j.jhsa.2021.05.022. Epub 2021 Jul 16.
10
Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data.溶组织梭状芽孢杆菌胶原酶治疗后掌腱膜挛缩复发情况(CORDLESS [胶原酶用于掌腱膜挛缩减少的长期安全性评估研究]):5年数据
J Hand Surg Am. 2015 Aug;40(8):1597-605. doi: 10.1016/j.jhsa.2015.04.036. Epub 2015 Jun 18.

本文引用的文献

1
Current Concepts in the Management of Dupuytren Disease of the Hand.手部杜普伊特伦挛缩症的治疗现状。
J Am Acad Orthop Surg. 2021 Jun 1;29(11):462-469. doi: 10.5435/JAAOS-D-20-00190.
2
Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: 2-Year Follow-up.胶原酶注射治疗杜普伊特伦挛缩:2 年随访。
Clin Orthop Surg. 2019 Sep;11(3):332-336. doi: 10.4055/cios.2019.11.3.332. Epub 2019 Aug 12.
3
Fasciectomy for Dupuytren Contracture.
Hand Clin. 2018 Aug;34(3):351-366. doi: 10.1016/j.hcl.2018.04.002.
4
Treatment of Dupuytren Contracture With Injectable Collagenase Within the Veterans Affairs System.
JAMA Surg. 2017 Feb 1;152(2):204-205. doi: 10.1001/jamasurg.2016.3605.
5
The Impact of Collagenase Clostridium histolyticum Introduction on Dupuytren Treatment Patterns in the United States.溶组织梭状芽孢杆菌胶原酶引入对美国杜普伊特伦挛缩治疗模式的影响
J Hand Surg Am. 2016 Oct;41(10):963-968. doi: 10.1016/j.jhsa.2016.07.090. Epub 2016 Aug 18.
6
Salvage palmar fasciectomy after initial treatment with collagenase clostridium histolyticum.在用溶组织梭状芽孢杆菌胶原酶进行初始治疗后行挽救性掌筋膜切除术。
Plast Reconstr Surg. 2015 Jun;135(6):1000e-1006e. doi: 10.1097/PRS.0000000000001282.
7
A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries.一项针对西方国家普通人群中 Dupuytren 病患病率的系统评价和荟萃分析。
Plast Reconstr Surg. 2014 Mar;133(3):593-603. doi: 10.1097/01.prs.0000438455.37604.0f.
8
Prevalence of Dupuytren disease in The Netherlands.荷兰的杜普伊特伦病流行情况。
Plast Reconstr Surg. 2013 Aug;132(2):394-403. doi: 10.1097/PRS.0b013e3182958a33.
9
Surgical findings in the treatment of Dupuytren's disease after initial treatment with clostridial collagenase (Xiaflex).用梭菌胶原酶(Xiaflex)初始治疗后掌腱膜挛缩症的手术治疗结果
J Hand Surg Eur Vol. 2014 Jun;39(5):463-5. doi: 10.1177/1753193413488305. Epub 2013 May 6.
10
Prevalence, incidence, and treatments of Dupuytren's disease in the United States: results from a population-based study.美国掌腱膜挛缩症的患病率、发病率及治疗情况:一项基于人群研究的结果
Hand (N Y). 2011 Jun;6(2):149-58. doi: 10.1007/s11552-010-9306-4. Epub 2010 Nov 16.

胶原酶注射治疗掌腱膜挛缩症后行有限掌腱膜切除术的围手术期并发症

Perioperative Complications Associated With Limited Surgical Fasciectomy After Collagenase Clostridium Histolyticum for Dupuytren Contracture.

机构信息

Brigham and Women's Hospital, Boston, MA, USA.

Harvard Medical School, Boston, MA, USA.

出版信息

Hand (N Y). 2024 Sep;19(6):946-950. doi: 10.1177/15589447231160288. Epub 2023 Apr 4.

DOI:10.1177/15589447231160288
PMID:37016563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11342708/
Abstract

BACKGROUND

The purpose of this study was to determine the perioperative complication rate of surgical fasciectomy following previous treatment with collagenase clostridium histolyticum (CCH) treatment in patients with Dupuytren disease.

METHODS

A retrospective review of all patients at a large health system undergoing CCH treatment and subsequent limited surgical fasciectomy for recurrence on the same digit between 2010 and 2020 was performed. Fifty-two patients with 62 affected digits met inclusion criteria, and cases were reviewed for preoperative demographics, treatment characteristics, clinical outcomes, and perioperative complications.

RESULTS

Fifty-five digits in 48 patients were treated with CCH and underwent subsequent limited surgical fasciectomy. Of all digits in the present study, 3 (6.3%) had a documented surgical complication following open surgical fasciectomy. There were zero postoperative infections, vascular injuries, or tendon injuries. The rate of nerve injury was 2.1%. The rate of postoperative skin necrosis was 4.2%. These rates were comparable or lower than those of historical published data.

CONCLUSIONS

The rate of perioperative complications in patients undergoing limited surgical fasciectomy after previous CCH treatment is low. The findings of this study will aid the counseling of Dupuytren patients in deciding whether to pursue treatment with CCH versus open surgical fasciectomy.

摘要

背景

本研究旨在确定先前接受胶原酶梭菌(CCH)治疗的患者在患有杜普伊特伦病后接受手术筋膜切开术的围手术期并发症发生率。

方法

对 2010 年至 2020 年期间在大型医疗系统中接受 CCH 治疗且同一手指上出现复发的患者进行回顾性研究,对接受 CCH 治疗且随后在同一手指上进行有限手术筋膜切开术的所有患者进行回顾性研究。52 例患者的 62 个受累手指符合纳入标准,对患者的术前人口统计学、治疗特征、临床结果和围手术期并发症进行了病例回顾。

结果

55 个手指在 48 例患者中接受 CCH 治疗,并随后接受了有限的手术筋膜切开术。在本研究的所有手指中,有 3 个(6.3%)在开放性手术筋膜切开术后有记录的手术并发症。术后无感染、血管损伤或肌腱损伤。神经损伤的发生率为 2.1%。术后皮肤坏死的发生率为 4.2%。这些比率与历史发表的数据相当或更低。

结论

在先前接受 CCH 治疗的患者中,接受有限手术筋膜切开术的围手术期并发症发生率较低。本研究的结果将有助于对杜普伊特伦病患者进行咨询,以决定是否采用 CCH 治疗还是开放性手术筋膜切开术。